Angiographic Geometric Changes of the Lumen Arterial Wall After Bioresorbable Vascular Scaffolds and Metallic Platform Stents at 1-Year Follow-Up

Gomez‐Lara, Josep; Brugaletta, Salvatore; Farooq, Vasim; Geuns, Robert Jan van; Bruyne, Bernard De; Windecker, Stephan; McClean, Dougal; Thuesen, Leif; Dudek, Dariusz; Koolen, Jacques; Whitbourn, Robert; Smits, Pieter C.; Chevalier, Bernard; Morel, Marie‐Angèle; Dorange, Cécile; Veldhof, Susan; Rapoza, Richard; García‐García, Héctor M.; Ormiston, John A.; Serruys, Patrick W.

doi:10.1016/j.jcin.2011.04.009

Cited by 51 publications

(30 citation statements)

References 23 publications

(33 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Curvature and angulation were measured before and after implantation and at follow-up with the same angiographic views (maximum difference of 10°) using the CAAS analysis system (CAAS 5.9 research version; Pie Medical Imaging BV, Maastricht, The Netherlands). 8 In brief, curvature is defined as the infinitesimal rate of change in the tangent vector at each point of the centerline. The software automatically detects the lumen contours of the selected segment and configures the centerline.…”

Section: Quantitative Coronary Angiographic Analysis Of Vessel Geometmentioning

confidence: 99%

Serial Observation of Drug-Eluting Absorbable Metal Scaffold

Waksman

Prati

Bruining

et al. 2013

Circ: Cardiovascular Interventions

Self Cite

View full text Add to dashboard Cite

1,2 stent thrombosis, especially at the late phase, remains a major concern, probably related to delayed healing, chronic inflammation, and impaired endothelialization.3 Furthermore, metallic stents are associated with artifacts in noninvasive imaging of MRI or multislice computed tomography, impairment of vessel geometry, and often jailing of side branches. Because of their permanent nature, metallic stents can also induce neoatherosclerosis during long-term follow-up. 4 Polymeric bioabsorbable temporary scaffolds have been developed to resolve these limitations. Second-generation bioabsorbable everolimus-eluting scaffold systems (BVS 1.1, ABSORB; Abbott Vascular, Santa Clara, CA) have shown a late lumen loss at 12 months similar to that seen with permanent everolimus-eluting stents (EES), along with a major adverse cardiac event rate of 7.1%. 5 In addition, unlike permanent metallic stents, interesting observations of the bioresorbable vascular scaffold technology are vessel lumen enlargement during follow-up and the ability of the vessel to Background-The drug-eluting absorbable metal scaffold has demonstrated feasibility, safety, and promising clinical and angiographic outcomes at 12 months in human coronary arteries. This study aimed to evaluate the degradation rate and long-term vascular responses to drug-eluting absorbable metal scaffold. Methods and Results-BIOSOLVE-I was a multicenter, single-arm, first-in-man trial assessing the safety and performance of drug-eluting absorbable metal scaffold in 46 patients with coronary artery disease. Patients who underwent serial invasive imaging, such as quantitative coronary angiography, intravascular ultrasound, and optical coherence tomography, at 6 and 12 months were included in this study. From postimplantation to follow-up, arterial curvature and angulation were significantly increased by the degradation process. The greatest increase was seen from postimplantation to 6 months. The systolic-diastolic changes of the curvature and angulation gradually improved throughout the follow-up period. At the site of implantation, vasoconstriction (−10% mean reduction) was observed during the acetylcholine test at 6 months. The average percent hyperechogenicity of the scaffolded segments showed a continuous decrease over time, with the most pronounced changes within the first 6 months (from 22.1±7.0% to 15.8±3.7%; P<0.001). Struts discernible on optical coherence tomography at 6 and 12 months showed full neointimal coverage, with stabilization of the mean scaffold area from 6 to 12 months. Furthermore, the mean neointimal area (1.55±0.51 versus 1.58±0.34 mm 2 ; P=0.794) remained unchanged from 6 to 12 months. Conclusions-This

show abstract

Section: Quantitative Coronary Angiographic Analysis Of Vessel Geometmentioning

confidence: 99%

Serial Observation of Drug-Eluting Absorbable Metal Scaffold

Waksman

Prati

Bruining

et al. 2013

Circ: Cardiovascular Interventions

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

“…[8][9][10] Permanent metallic platform stents also indefinitely impair the physiological vasomotor functioning of the vessel; hence the coronary geometry and systo-diastolic movement of coronary arteries treated with metallic stents remain similar up to a year after implantation. 9,10 Bioresorbable vascular scaffolds have the potential to overcome these limitations as they provide a temporary scaffolding which disappears after 2-3 years, liberating the treated vessel, and can help to restore the vessel's original shape, preserving laminar blood flow, reducing the plaque-to-media ratio and restoring the vasomotion, pulsatility, cyclical strain, adaptive shear stress and mechanotransduction of the vessel. 8,9,11 Following PCI, the absence of any residual foreign material and restoration of functional endothelial coverage can also reduce the risk of stent thrombosis, myocardial infarction, sudden death and the need for long-term dual antiplatelet therapy; in addition, PCI does not exclude the possibility of future graft anastomosis in case the need for future bypass surgery arises.…”

Section: Discussionmentioning

confidence: 99%

“…8,9 In addition, implanting a long metallic drug-eluting stent at the distal coronary bed could potentially affect coronary flow or the outcome of future CABG surgeries. 9,10 Nevertheless, metallic stents were also implanted at proximal sites due to the limitations of bioresorbable vascular scaffolds for large vessels, bifurcations (i.e. the left main trunk lesion in the current patient) and severely calcified lesions.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

A Combination of Drug-Eluting Stents and Bioresorbable Vascular Scaffolds in the Treatment of Multivessel Coronary Artery Disease *

Zilio

Napodano

2016

SQUMJ

View full text Add to dashboard Cite

“…18 At 6-or 12-month followup, the anatomical configuration of the arteries treated with the ABSORB BVS allowed restoration of coronary geometry to values close to those measured before implantation. 19 Late vascular remodeling in metallic stent and BVS One possible fate of the dilated but caged lesion is an intra-stent lumen reduction by intra-stent neointimal tissue growth (negative remodeling), even if the cytostatic drug slows down or postpones the phenomenon. But in many of the cases there is retraction of the surrounding vessel wall from the metallic cage.…”

Section: Bvs and Vascular Geometrymentioning

confidence: 99%

Bioabsorbable Vascular Scaffold: A Revolution in Coronary Intervention

2014

View full text Add to dashboard Cite

Since the advent of percutaneous coronary angioplasty in 1977, immense experiment has been done to improve the outcome of the patients with coronary artery disease. Lot of trials have been done with angioplasty, bare metal stents, drug eluting stents, drug eluting balloons and other devices. Bioabsorbable vascular stents are relatively newcomers in this field with a lot of hope. We tried to update the latest status of Bioabsorbable vascular stents in this review, specially the short and midterm safety and efficacy and some of their limitations. DOI: http://dx.doi.org/10.3329/cardio.v6i2.18359 Cardiovasc. j. 2014; 6(2): 149-163

show abstract

Angiographic Geometric Changes of the Lumen Arterial Wall After Bioresorbable Vascular Scaffolds and Metallic Platform Stents at 1-Year Follow-Up

Cited by 51 publications

References 23 publications

Serial Observation of Drug-Eluting Absorbable Metal Scaffold

Serial Observation of Drug-Eluting Absorbable Metal Scaffold

A Combination of Drug-Eluting Stents and Bioresorbable Vascular Scaffolds in the Treatment of Multivessel Coronary Artery Disease *

Bioabsorbable Vascular Scaffold: A Revolution in Coronary Intervention

Contact Info

Product

Resources

About